Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.55 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928759 | 0.88 | KMT2A (0.57) | KMT2A | |
| SCHEMBL17024452 | 0.88 | LMNA (0.53) | MAPTKMT2A | |
| SCHEMBL3584866 | 0.87 | PSEN1 (0.43) | MAOBMAOAMAPTKMT2AMEN1 | |
| SCHEMBL5047908 | 0.87 | PARP1 (0.54) | MAPTKMT2AMEN1 | |
| SCHEMBL22251779 | 0.86 | HPGD (0.54) | MAOBABCB1MAPTKMT2AMEN1 | |
| SCHEMBL5353265 | 0.86 | SMN1; SMN2 (0.53) | MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8556615 | 0.85 | POLB (0.43) | MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL18038110 | 0.85 | KMT2A (0.48) | MAPTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL14501385 | 0.84 | PSEN1 (0.45) | MAPTKMT2AMEN1 | |
| SCHEMBL7396086 | 0.83 | KMT2A (0.61) | MAOBMAOAMAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120130076-A1 | Synthetic Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-0888303-B1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD PHARMA INC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-0776327-B1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0776327-A4 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0776327-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006097-A1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | MAOB 2516/4885MAOA 3442/4885ABCB1 3476/4885 |
| US-20120130076-A1 | Synthetic Multimerizing Agents | FKBP1B, FKBP2, FKBP14 | MAOB 2214/4885MAOA 2979/4885ABCB1 2386/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | MAOB 2108/4885MAOA 2838/4885ABCB1 2012/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | MAOB 3066/4885MAOA 3659/4885ABCB1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.